Literature DB >> 24372462

Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis.

Catherine E Cooke1, Helen Y Lee, Shan Xing.   

Abstract

BACKGROUND: Antiretroviral therapy (ART) extends life for patients with human immunodeficiency virus (HIV) infection. However, HIV treatment is lifelong, and adherence presents a special challenge. Suboptimal adherence to ART may lead to disease progression and virologic failure. Earlier studies with combination ART demonstrated that as much as 90%-95% adherence was needed to prevent disease progression.
OBJECTIVE: To measure adherence to ART regimens in commercially insured patients with HIV infection and analyze the clinical and demographic factors associated with ≥ 90% adherence.
METHODS: This study used retrospective claims data from a Mid-Atlantic states MCO. Members 18 years and older with an HIV diagnosis identified by medical claims were included in the cohort, and pharmacy claims were retrieved for these members. An ART regimen was established for each patient within a 120-day period after the last physician's visit occurring between January 1, 2010, and August 31, 2010. For patients who received an ART regimen recommended by the U.S. Department of Health and Human Services (HHS) 2011 Antiretroviral Guidelines, adherence, as measured by medication possession ratio (MPR), was calculated based on pharmacy claims for 12 months after the end of the 120-day period. Logistic regression was used to examine the association between MPR ≥ 90% and age, sex, type of health plan, use of single-tablet regimens (STR), inpatient and outpatient utilization, and direct health care costs.
RESULTS: Of the 4,547 adults with HIV diagnosis, 3,528 (77.6%) had received at least 1 antiretroviral. An HHS-recommended ART regimen was identified in 2,377 patients with 1,136 (47.8%) receiving STR. Mean MPR for patients on an HHS-recommended ART regimen was 91.5% ± 14.0 with 73.1% of patients having achieved MPR ≥ 90%. In univariate analyses, sex, number of outpatient visits, cost of inpatient care, and use of STR were significantly associated with MPR ≥ 90%. In multivariate analysis, only male sex (P = 0.027) and the use of STR (P = 0.009) were positively associated with MPR ≥ 90%. Patients on STR were 1.3 times more likely to achieve at least 90% adherence.
CONCLUSIONS: Adherence is a challenge for patients with HIV, and more than a quarter of patients who were on an HHS-recommended ART regimen failed to achieve an accepted adherence MPR threshold of ≥ 90%. Use of STR was associated with an increased likelihood of achieving adherence of at least 90%. Interventions to improve ART adherence are needed, and STR may be an effective strategy as it decreases pill burden.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24372462     DOI: 10.18553/jmcp.2014.20.1.86

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  17 in total

Review 1.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 2.  Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model.

Authors:  Carol W Holtzman; Judy A Shea; Karen Glanz; Lisa M Jacobs; Robert Gross; Janet Hines; Karam Mounzer; Rafik Samuel; Joshua P Metlay; Baligh R Yehia
Journal:  AIDS Care       Date:  2015-02-11

3.  Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome.

Authors:  Rebecca Reece; Allison Delong; D'Antuono Matthew; Karen Tashima; Rami Kantor
Journal:  J Clin Virol       Date:  2018-05-21       Impact factor: 3.168

4.  Attrition and Opportunities Along the HIV Care Continuum: Findings From a Population-Based Sample, North West Province, South Africa.

Authors:  Sheri A Lippman; Starley B Shade; Alison M El Ayadi; Jennifer M Gilvydis; Jessica S Grignon; Teri Liegler; Jessica Morris; Evasen Naidoo; Lisa M Prach; Adrian Puren; Scott Barnhart
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

5.  Antiretroviral Therapy Adherence and Use of an Electronic Shared Medical Record Among People Living with HIV.

Authors:  Parya Saberi; Sheryl L Catz; Wendy A Leyden; Christine Stewart; James D Ralston; Michael A Horberg; Louis Grothaus; Michael J Silverberg
Journal:  AIDS Behav       Date:  2015-06

6.  Police abuse and care engagement of people with HIV who inject drugs in Ukraine.

Authors:  Samantha F Schoenberger; Bulat Idrisov; Yuliia Sereda; Tetiana Kiriazova; Olena Makarenko; Sally Bendiks; Nishtha Ahuja; Arunima Dutta; Timothy Flanigan; Fizza S Gillani; Karsten Lunze
Journal:  Glob Public Health       Date:  2022-03-28

7.  Physician network connections to specialists and HIV quality of care.

Authors:  Chad Stecher
Journal:  Health Serv Res       Date:  2021-02-04       Impact factor: 3.734

8.  Promoting antiretroviral therapy adherence habits: a synthesis of economic and psychological theories of habit formation.

Authors:  Chad Stecher; Sebastian Linnemayr
Journal:  AIDS       Date:  2021-04-01       Impact factor: 4.632

9.  Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients.

Authors:  Valentina Perrone; Dario Cattaneo; Sonia Radice; Diego Sangiorgi; Augusto B Federici; Maria Rita Gismondo; Massimo Medaglia; Valeria Micheli; Stefania Vimercati; Enza Pallone; Luca Degli Esposti; Emilio Clementi
Journal:  Clinicoecon Outcomes Res       Date:  2014-07-14

10.  Evaluation of the Sociodemographic, Behavioral and Clinical Influences on Complete Antiretroviral Therapy Adherence Among HIV-Infected Adults Receiving Medical Care in Houston, Texas.

Authors:  Pagna Sok; Osaro Mgbere; Lisa Pompeii; Ekere James Essien
Journal:  HIV AIDS (Auckl)       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.